CA3173633A1 - Sialic acid compositions for use in inhibiting and treating coronavirus infection - Google Patents

Sialic acid compositions for use in inhibiting and treating coronavirus infection Download PDF

Info

Publication number
CA3173633A1
CA3173633A1 CA3173633A CA3173633A CA3173633A1 CA 3173633 A1 CA3173633 A1 CA 3173633A1 CA 3173633 A CA3173633 A CA 3173633A CA 3173633 A CA3173633 A CA 3173633A CA 3173633 A1 CA3173633 A1 CA 3173633A1
Authority
CA
Canada
Prior art keywords
sialic acid
nana
acid
cov
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173633A
Other languages
English (en)
French (fr)
Inventor
Jan Remmereit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lifescience AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3173633A1 publication Critical patent/CA3173633A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3173633A 2020-04-01 2021-03-31 Sialic acid compositions for use in inhibiting and treating coronavirus infection Pending CA3173633A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003477P 2020-04-01 2020-04-01
US63/003,477 2020-04-01
PCT/IB2021/000200 WO2021198774A1 (en) 2020-04-01 2021-03-31 Sialic acid compositions for use in inhibiting and treating coronavirus infection

Publications (1)

Publication Number Publication Date
CA3173633A1 true CA3173633A1 (en) 2021-10-07

Family

ID=76250375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173633A Pending CA3173633A1 (en) 2020-04-01 2021-03-31 Sialic acid compositions for use in inhibiting and treating coronavirus infection

Country Status (9)

Country Link
US (3) US11813271B2 (https=)
EP (1) EP4125926A1 (https=)
JP (1) JP2023520703A (https=)
KR (1) KR20220161413A (https=)
CN (1) CN115461057A (https=)
AU (1) AU2021247584B2 (https=)
BR (1) BR112022019685A2 (https=)
CA (1) CA3173633A1 (https=)
WO (1) WO2021198774A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230226088A1 (en) * 2020-06-09 2023-07-20 The Texas A&M University System Therapeutics for treatment of covid-19 symptoms
WO2023104402A1 (en) 2021-12-09 2023-06-15 Frieslandcampina Nederland B.V. Milk fraction that inhibits covid-19 infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
EP2364139A2 (en) * 2008-11-10 2011-09-14 Life Science Nutrition AS Ngna compositions and methods of use
AU2010315024B2 (en) * 2009-11-06 2015-02-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
CN111787925A (zh) * 2017-10-11 2020-10-16 生命科学股份有限公司 N-乙酰神经氨酸组合物和使用方法
CN111481560A (zh) * 2020-04-23 2020-08-04 菌维他(北京)医疗科技有限公司 唾液酸及衍生物在制备防治冠状病毒疾病的药品中的应用
CN111658631A (zh) 2020-06-11 2020-09-15 广东盛普生命科技有限公司 没食子酸及其衍生物和结构类似物在制备抗冠状病毒药物方面的应用

Also Published As

Publication number Publication date
US20260083762A1 (en) 2026-03-26
US20240148763A1 (en) 2024-05-09
KR20220161413A (ko) 2022-12-06
JP2023520703A (ja) 2023-05-18
WO2021198774A1 (en) 2021-10-07
AU2021247584A1 (en) 2022-10-20
BR112022019685A2 (pt) 2022-11-22
EP4125926A1 (en) 2023-02-08
CN115461057A (zh) 2022-12-09
US11813271B2 (en) 2023-11-14
US12390481B2 (en) 2025-08-19
US20230128687A1 (en) 2023-04-27
AU2021247584B2 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US20260083762A1 (en) Sialic acid compositions for the use of inhibiting and treating coronavirus infection
US11672814B2 (en) NGNA compositions and methods of use
EP3694524B1 (en) N-acetylneuraminic acid compositions and their use for inhibiting or treating ailments of the upper respiratory tract
US20200054609A1 (en) Nasal Compositions and Method of Use Thereof
US20020128273A1 (en) Composition and method for treating the effects of diseases and maladies
US20010044411A1 (en) Composition and method for treating the effects of diseases and maladies
US11752108B2 (en) Gold particles including an oleo-gum resin and/or a derivative thereof and methods of preparing and using the same
HK40084501A (en) Sialic acid compositions for use in inhibiting and treating coronavirus infection
Sataloff et al. Medications and the voice
RO138617A0 (ro) Compoziţie farmaceutică inovatoare sub formă de spray oral pentru sănătatea respiratorie
US20230233456A1 (en) Compositions and methods for treating coronavirus
US20260014198A1 (en) Antiviral Composition for Animals
WO2026072659A1 (en) Formulations of segmented filamentous bacteria-induced metabolites and methods of use thereof
US20250134924A1 (en) Composition for Prevention and Treatment of Bacterial and Viral Infections and Inflammation
WO2021204520A1 (en) Composition comprising resveratrol
EP1249242A1 (en) Natural-Phytotherapic composition based on hydroglyceric extracts for aerosol therapy
HK1050996B (en) Natural-phytotherapic composition based on hydroglyceric extracts for aerosol therapy
HK1050996A1 (en) Natural-phytotherapic composition based on hydroglyceric extracts for aerosol therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250731

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250731

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260228